METTL3‐mediated m6A modification causes MYC upregulation and is responsible for the AraC resistance of the AML cells.[73] m6A plays a role in cisplatin resistance in gastric[46, 74] and bladder cancer[75] cells due to alteration in the apoptotic process. Here, METTL3 is linked to urinary bladder carcinoma.